Metronidazol Actavis (Metronidazole)

Metronidazole penetrates microbial cells and is reduced to reactive nitro radicals under anaerobic conditions. These radicals damage DNA and inhibit nucleic acid synthesis, leading to bacterial and protozoal cell death, thereby reducing infection and inflammation on the skin.

The specific dosage and frequency of Metronidazol Actavis are determined by the prescribing healthcare professional based on the severity of the condition, the area of skin involved, and patient factors. Patients should follow the prescriber’s instructions and the product label.

Safety data for topical metronidazole during pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their clinician before starting treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details and any required import documentation.

Metronidazol Actavis belongs to the nitroimidazole class, offering both antibacterial and antiprotozoal activity, which differentiates it from many topical antibiotics that target only bacteria. It is particularly effective against anaerobic organisms and is often preferred for rosacea and acne where these microbes play a role.

Store Metronidazol Actavis at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain stability and potency throughout its shelf life.

The product is applied topically to clean, dry skin. A thin layer is spread over the affected area, usually once or twice daily, as directed by the prescriber. Hands should be washed after application, and the treated area should not be covered with occlusive dressings unless advised.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and rare systemic toxicity if significant absorption occurs. Patients should discontinue use and seek immediate medical attention if they develop widespread rash, blistering, fever, or signs of an allergic reaction.

Individuals with a known hypersensitivity to metronidazole, other nitroimidazoles, or any component of the formulation should avoid this product. It is also contraindicated on large areas of broken or ulcerated skin, and in patients who cannot abstain from alcohol during therapy.